U.S., Aug. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07129707) titled 'Nasal High-flow Oxygen Therapy During Acute Exercise in Fibrotic Interstitial Lung Disease' on Aug. 09.
Brief Summary: Hallmarks of fibrotic interstitial lung disease (f-ILD) include severe hypoxemia, dyspnea and exercise limitation. Although ambulatory oxygen (O2) therapy is widely prescribed, standard low-flow O2 systems (nasal prongs) fail to meet patients' inspiratory demand on exertion resulting in incomplete correction of hypoxemia and limited symptomatic relief. Nasal high-flow O2 therapy (NHFO2) delivers heated, humidified, and O2-enriched air at high flow rates. It has recently emerged as a promising alternative to overcome...